Premium
The use of selective Th2 blocker dupilumab for the treatment of atopic dermatitis in a heart transplant patient: Case report
Author(s) -
Sklover Lindsay,
Nielson Colton,
De Benedetto Anna
Publication year - 2019
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.13144
Subject(s) - medicine , dupilumab , atopic dermatitis , immunosuppression , calcineurin , dermatology , tacrolimus , rash , incidence (geometry) , immune dysregulation , palpitations , sirolimus , eczematous dermatitis , immunology , immune system , transplantation , physics , optics
Abstract Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by relapsing eczematous rash with severe pruritus and recurrent infection. Topical emollients and immune‐modulators (e.g., corticosteroids and calcineurin inhibitor) are first‐line therapies for acute flares. In severe refractory cases, systemic immunosuppression may be required. Increased incidence of AD has been documented in heart‐transplant children who receive their transplant or thymectomy before the age of 1 year. The treatment of these patients remains a conundrum for dermatologists. We present a case report of a chronically immunosuppressed transplant patient with severe AD treated with dupilumab and in remission for over 2 years with minimal side effects. We will also discuss impact of transplant immunosuppression in the pathogenesis of AD.